REACX PHARMACEUTICALS AWARDED $10.35 MILLION GRANT TO ADVANCE NALMEFENE IMPLANT FOR OPIOID RELAPSE PREVENTION
Implant to use the Company’s proprietary ProNeura™ drug delivery system SOUTH SAN FRANCISCO, CA, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- ReacX Pharmaceuticals, Inc. (“ReacX” or the “Company”), a company focused on developing and …